Zoetis (NYSE:ZTS) Given New $115.00 Price Target at JPMorgan Chase & Co.

Zoetis (NYSE:ZTS) had its target price cut by JPMorgan Chase & Co. from $130.00 to $115.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also recently issued reports on the company. TD Cowen decreased their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. William Blair reiterated a “market perform” rating on shares of Zoetis in a research report on Thursday. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, Citigroup lowered their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $115.50.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $72.53 on Friday. The company has a market cap of $30.41 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 1.34 and a beta of 0.74. Zoetis has a 12 month low of $71.47 and a 12 month high of $160.48. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a 50-day simple moving average of $76.66 and a 200-day simple moving average of $100.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 70.95%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts anticipate that Zoetis will post 6.2 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Insider Buying and Selling at Zoetis

In other news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Institutional Investors Weigh In On Zoetis

Several institutional investors have recently bought and sold shares of ZTS. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Zoetis during the 2nd quarter valued at $25,000. Dunhill Financial LLC increased its holdings in Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares in the last quarter. Prosperity Bancshares Inc acquired a new stake in Zoetis in the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC purchased a new position in Zoetis in the first quarter valued at about $28,000. Finally, Root Financial Partners LLC lifted its stake in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.